Chargement…
84 entreprises que nous couvrons, dont 78 notées
Toutes les entreprises d’ici passées par les mêmes cinq vérifications sur la croissance et la génération de trésorerie. Cela décrit le sous-secteur tel qu’il publie aujourd’hui — pas laquelle de ces valeurs acheter.
| TEVA | TEVA PHARMACEUTICAL INDUSTRIES LIMITED | A | 45,7B $US | 39,19 $US | 65,32 | 17,3B $US | 4,1 % |
| HLN | Haleon plc | B+ | 41,4B $US | 9,26 $US | 18,87 | 14,6B $US | 15,1 % |
| TAK | Takeda Pharmaceutical Company Limited | B | 30,3B $US | 18,86 $US | 44,01 | 28,7B $US | -3,4 % |
| ZTS | Zoetis Inc. | A+ | 29,4B $US | 71,05 $US | 11,71 | 9,5B $US | 27,5 % |
| VTRS | VIATRIS INC. | C | 20,5B $US | 17,83 $US | — | 14,7B $US | -23,9 % |
| UTHR | United Therapeutics Corporation | B+ | 20,4B $US | 475,45 $US | 17,02 | 3,2B $US | 41,6 % |
| NBIX | NEUROCRINE BIOSCIENCES INC | A+ | 14,1B $US | 138,40 $US | 20,29 | 3,4B $US | 20,9 % |
| ELAN | Elanco Animal Health Incorporated | A | 11,1B $US | 22,31 $US | — | 5B $US | -4,0 % |
| RDY | DR. REDDY’S LABORATORIES LIMITED | B+ | 10,2B $US | 12,25 $US | 17,35 | 3,5B $US | 12,8 % |
| ALKS | Alkermes plc. | B | 6,9B $US | 40,85 $US | 107,50 | 1,7B $US | 4,0 % |
| HIMS | HIMS & HERS HEALTH, INC. | A- | 6,8B $US | 29,42 $US | — | 2,6B $US | -5,5 % |
| LNTH | Lantheus Holdings, Inc. | A+ | 6,5B $US | 99,74 $US | 24,15 | 1,6B $US | 17,7 % |
| AMRX | AMNEAL PHARMACEUTICALS, INC. | C | 6,3B $US | 19,77 $US | 40,35 | 3,1B $US | 5,0 % |
| KNSA | Kiniksa Pharmaceuticals International, plc | A | 6,2B $US | 75,08 $US | 82,51 | 754M $US | 9,7 % |
| LQDA | LIQUIDIA CORPORATION | A+ | 6,1B $US | 68,43 $US | 49,23 | 450,9M $US | 30,7 % |
| INDV | Indivior Pharmaceuticals, Inc. | D | 4,2B $US | 35,82 $US | 12,84 | 1,3B $US | 26,7 % |
| AMLX | Amylyx Pharmaceuticals, Inc. | D | 3,3B $US | 29,49 $US | — | 0,00 $US | — |
| RGC | Regencell Bioscience Holdings Limited | non notée | 3,1B $US | 6,17 $US | — | — | — |
| SUPN | SUPERNUS PHARMACEUTICALS, INC. | C- | 2,5B $US | 42,66 $US | — | 830,4M $US | -13,2 % |
| HCM | HutchMED (China) LIMITED | D | 2,4B $US | 13,94 $US | 26,81 | 549,1M $US | 3,3 % |
| TRLV | TRULIEVE CANNABIS CORP. | D | 2,4B $US | 12,21 $US | — | 1,1B $US | -41,8 % |
| PBH | PRESTIGE CONSUMER HEALTHCARE INC. | C+ | 2,2B $US | 46,61 $US | 13,06 | 1,1B $US | 15,6 % |
| BCRX | BIOCRYST PHARMACEUTICALS, INC. | A | 2,2B $US | 8,59 $US | — | 940,6M $US | -40,9 % |
| PRGO | Perrigo Company plc | F- | 2,1B $US | 15,42 $US | — | 4,1B $US | -41,9 % |
| BHC | Bausch Health Companies Inc. | A | 2,1B $US | 5,69 $US | — | 10,9B $US | -10,1 % |
| ALVO | ALVOTECH | B | 1,8B $US | 5,75 $US | 57,50 | 586,3M $US | 4,8 % |
| XERS | XERIS BIOPHARMA HOLDINGS, INC. | F- | 1,7B $US | 9,10 $US | — | 335,4M $US | -5,1 % |
| ETON | Eton Pharmaceuticals, Inc. | A+ | 1,6B $US | 57,68 $US | — | 105,6M $US | 12,0 % |
| ANIP | ANI PHARMACEUTICALS, INC | A+ | 1,6B $US | 74,00 $US | 15,98 | 978,4M $US | 11,1 % |
| PAHC | Phibro Animal Health Corporation | B | 1,4B $US | 34,45 $US | 14,12 | 1,5B $US | 6,6 % |
| HROW | Harrow, Inc. | B- | 1,2B $US | 33,07 $US | — | 275,6M $US | -13,5 % |
| CRON | CRONOS GROUP INC. | A | 1,2B $US | 3,34 $US | 16,70 | 179,1M $US | 39,1 % |
| AMPH | Amphastar Pharmaceuticals, Inc. | A+ | 1,1B $US | 26,13 $US | 15,46 | 730M $US | 10,8 % |
| PCRX | PACIRA BIOSCIENCES, INC. | A | 1B $US | 25,12 $US | 71,77 | 746,2M $US | 2,0 % |
| COLL | Collegium Pharmaceutical, Inc. | A+ | 733,5M $US | 22,53 $US | 18,17 | 808,2M $US | 5,9 % |
| IRWD | IRONWOOD PHARMACEUTICALS, INC. | C+ | 682,4M $US | 4,13 $US | 5,36 | 389,3M $US | 33,4 % |
| AQST | Aquestive Therapeutics, Inc. | C | 587,4M $US | 4,68 $US | — | 54,1M $US | -144,6 % |
| TLRY | Tilray Brands, Inc. | C- | 562,5M $US | 4,13 $US | — | 915,5M $US | -13,3 % |
| GLAS | Glass House Brands Inc. | D- | 557,2M $US | 6,80 $US | — | 152,9M $US | -33,7 % |
| EOLS | EVOLUS, INC. | B | 526,4M $US | 7,97 $US | — | 316,5M $US | -10,8 % |
| KMDA | KAMADA LTD | C | 503M $US | 8,72 $US | 22,95 | 191,8M $US | 11,6 % |
| TKNO | ALPHA TEKNOVA, INC. | B- | 500,9M $US | 9,33 $US | — | 43,7M $US | -38,4 % |
| CGC | Canopy Growth Corp | D- | 398,3M $US | 0,94 $US | — | 207,3M $US | -79,2 % |
| EBS | EMERGENT BIOSOLUTIONS INC. | C | 348,1M $US | 6,79 $US | — | 770,2M $US | -23,0 % |
| BIOA | BIOAGE LABS, INC. | D- | 323,6M $US | 7,05 $US | — | 10,4M $US | -912,3 % |
| INCR | INTERCURE LTD. | C- | 284,9M $US | 5,21 $US | — | 88,2M $US | -13,2 % |
| EVO | Evotec SE | D- | 277,3M $US | 1,56 $US | — | 897M $US | -13,1 % |
| ANIK | Anika Therapeutics, Inc. | B- | 272,6M $US | 20,37 $US | — | 120,7M $US | -3,1 % |
| AKBA | AKEBIA THERAPEUTICS, INC. | C | 248,3M $US | 0,90 $US | — | 219,1M $US | -13,5 % |
| SIGA | Siga Technologies INC | F- | 247,9M $US | 3,45 $US | — | 53,7M $US | -5,2 % |
| ACB | AURORA CANNABIS INC | D | 230,6M $US | 4,10 $US | 145,20 | 226,3M $US | -42,4 % |
| ORGO | ORGANOGENESIS HOLDINGS INC. | B- | 181,4M $US | 1,41 $US | — | 457,5M $US | -18,4 % |
| CRDL | Cardiol Therapeutics Inc. | non notée | 171,4M $US | 1,71 $US | — | — | — |
| DERM | Journey Medical Corp | C- | 168,2M $US | 6,14 $US | — | 68,2M $US | -9,0 % |
| ADCT | ADC Therapeutics SA | D | 162,1M $US | 1,27 $US | — | 79,6M $US | -121,8 % |
| LFCR | LIFECORE BIOMEDICAL, INC. | D | 159M $US | 4,20 $US | — | 128,9M $US | -30,0 % |
| CPIX | Cumberland Pharmaceuticals Inc. | F- | 114M $US | 7,61 $US | — | 39,9M $US | -27,4 % |
| OGI | ORGANIGRAM HOLDINGS INC. | C- | 104,8M $US | 1,10 $US | — | 183M $US | -9,6 % |
| CTOR | Citius Oncology, Inc. | non notée | 97,6M $US | 1,05 $US | — | — | — |
| ZYBT | Zhengye Biotechnology Holding Limited | D | 61,8M $US | 1,31 $US | 35,03 | 17,3M $US | -60,0 % |
| SCYX | SCYNEXIS, Inc. | F- | 43,7M $US | 4,39 $US | 15,14 | 19,2M $US | -53,3 % |
| IMCC | IM Cannabis Corp. | C | 36,4M $US | 2,84 $US | — | 32,3M $US | -39,1 % |
| RMTI | ROCKWELL MEDICAL, INC. | B- | 33,7M $US | 8,37 $US | — | 69,4M $US | -7,3 % |
| CPHI | CHINA PHARMA HOLDINGS, INC. | C- | 32,3M $US | 0,75 $US | — | 3,9M $US | -114,3 % |
| BGM | BGM Group Ltd | F- | 27,2M $US | 0,24 $US | — | 37,9M $US | -52,6 % |
| AYTU | AYTU BIOPHARMA, INC | C | 24,8M $US | 2,28 $US | — | 57,6M $US | -24,8 % |
| TXMD | TherapeuticsMD, Inc. | F- | 23,7M $US | 2,05 $US | — | 3,3M $US | -6,6 % |
| RDHL | REDHILL BIOPHARMA LTD. | F- | 22,5M $US | 0,50 $US | — | 286K $US | -150,0 % |
| BFRI | Biofrontera Inc. | B- | 17,5M $US | 1,18 $US | — | 46,2M $US | -13,8 % |
| TLPH | TALPHERA, INC. | C- | 16,8M $US | 1,18 $US | — | 1K $US | -1 507 600,0 % |
| CABR | CARING BRANDS, INC. | F- | 12,8M $US | 1,24 $US | — | 4,2K $US | -183 255,2 % |
| APUS | APIMEDS PHARMACEUTICALS US, INC. | non notée | 10,9M $US | 7,25 $US | — | — | — |
| INM | INMED PHARMACEUTICALS INC. | D- | 7,6M $US | 1,38 $US | — | 4,5M $US | -278,7 % |
| SNOA | SONOMA PHARMACEUTICALS, INC. | B- | 6,1M $US | 1,27 $US | — | 21,9M $US | -10,3 % |
| GELS | Gelteq Limited | D- | 5,2M $US | 0,55 $US | — | 116,3K $US | -4 011,9 % |
| SBFM | Sunshine Biopharma Inc. | C- | 3,3M $US | 0,84 $US | — | 35,3M $US | -16,5 % |
| SHPH | SHUTTLE PHARMACEUTICALS HOLDINGS, INC. | non notée | 3M $US | 4,01 $US | — | — | — |
| UPC | Universe Pharmaceuticals INC | D- | 2,7M $US | 4,75 $US | — | 17,9B $US | -20,6 % |
| SXTC | China SXT Pharmaceuticals, Inc. | F- | 2,5M $US | 2,57 $US | — | 1,1M $US | -545,2 % |
| YCBD | cbdMD, Inc. | D- | 1,9M $US | 0,47 $US | — | 20,9M $US | -13,8 % |
| IXHL | Incannex Healthcare Inc. | F- | 1,7M $US | 3,32 $US | — | 0,00 $US | — |
| PRFX | PRF Technologies Ltd. | B- | 811,3K $US | 0,98 $US | — | 17K $US | -29 541,2 % |
| AKAN | AKANDA CORP. | F | 210,3K $US | 3,05 $US | 0,24 | 258,1K $US | -17 690,2 % |
| OPTH | Optimi Health Corp. | non notée | — | 4,82 $US | — | — | — |
Fondamentaux issus des documents déposés auprès de la SEC, cours issus de la dernière collecte de données de marché. Triez par n’importe quelle colonne ; les entreprises sans chiffre passent en dernier dans les deux sens.
Trié par capitalisation, de la plus grande à la plus petite ; cliquez sur une colonne pour retrier. Les entreprises sans chiffre passent en dernier dans les deux sens, parce qu’un PER manquant signifie une perte et non un titre bon marché. Rien ici n’est une recommandation.